Shockwave Therapy for Tendinopathy: What the Evidence Actually Says

Shockwave therapy has become one of the most commonly recommended interventions for tendinopathy in recent years. It's routinely offered by physiotherapists, sports medicine clinicians, and private clinics — often positioned as an evidence-based option for cases that haven't responded to exercise. Some patients arrive having already had a course; others are asking whether they should pursue it before starting a loading programme.

The question I want to address here is straightforward: what does the evidence actually support? Where is shockwave useful, where is it overused, and how should it fit into a tendinopathy management framework?

This is a clinical-level review. I've tried to read this literature carefully over the past few years, and my honest summary is that shockwave is a useful tool — with meaningful limitations that are frequently undersold.

Mechanism of Action: What Shockwave Is Doing

Extracorporeal shockwave therapy (ESWT) delivers acoustic pressure waves to tissue. Two types are in clinical use: focused ESWT (f-ESWT), which concentrates energy at a specific depth, and radial pressure wave therapy (RPWT), which disperses energy more broadly and is sometimes inaccurately marketed as shockwave.

The proposed mechanisms are several. Neurogenic effects — modulation of nociceptive signalling and substance P depletion — are often cited as the primary driver of the analgesic response. Mechanotransductive effects on tenocytes, stimulation of growth factor release (particularly TGF-β1 and IGF-1), and disruption of calcific deposits are also documented in vitro and in animal models.

The mechanistic picture is plausible. Whether those in vitro and animal-model findings translate meaningfully to clinical outcomes in degenerative human tendon is the question the trial literature is still working through.

Evidence by Condition

Lateral Elbow Tendinopathy (Tennis Elbow)

This is probably where the shockwave evidence is most mixed. Early meta-analyses were moderately positive, but several high-quality trials have struggled to demonstrate superiority over sham — particularly when exercise is adequately dosed in the comparator group.

Rompe et al. (2007) found that exercise combined with shockwave outperformed either alone at 12-month follow-up, which is probably the most clinically useful finding. Smidt et al.'s Lancet RCT (2002) is frequently cited as negative for shockwave — but the control group received corticosteroid injection, and the comparison is confounded by the poor long-term profile of injection in this population.

The honest summary for lateral elbow tendinopathy: shockwave provides short-to-medium term benefit in some patients, particularly those who can't tolerate loading initially. It should not be the primary treatment, and its effect size is modest when exercise is the comparator.

Achilles Tendinopathy

The Achilles evidence is more consistently positive, particularly for mid-portion presentations. Rompe et al. (2008) compared ESWT to the Alfredson eccentric protocol and found comparable outcomes at 4 months, with shockwave performing better at short-term follow-up. Their 2009 RCT combining eccentric loading with ESWT versus either alone showed superiority of the combined approach.

Insertional Achilles tendinopathy has been harder to study, in part because compression-avoidance principles mean the comparator exercise programme needs careful design. The limited evidence suggests shockwave may be particularly useful here — possibly because the calcific and compressive components of insertional pathology respond to the disruption mechanism in a way that pure exercise cannot achieve.

A 2020 systematic review (Habets et al.) found moderate-quality evidence that ESWT produces meaningful short-term pain reduction in mid-portion Achilles tendinopathy compared to sham. Effect sizes were moderate (SMD around 0.5–0.7). Duration of benefit at 12 months was less consistent across trials.

Patellar Tendinopathy

The patellar tendon literature is smaller but reasonably consistent. Focused ESWT has shown benefit in several RCTs, including the well-designed Zwerver et al. trial (2011), which found no benefit over sham — but notably used an in-season population where exercise compliance was necessarily limited. The Harnandez-Sanchez et al. and van Leeuwen et al. trials have been more positive.

In my reading of this literature, the patellar tendon evidence suggests similar conclusions to Achilles: shockwave is a useful adjunct, particularly for patients in whom heavy loading is not yet feasible. The combined approach — shockwave during early/mid rehab alongside progressive loading — has reasonable support.

Key Methodological Challenges in This Literature

Before drawing strong conclusions, it's worth naming the problems that make this evidence base difficult to interpret.

Sham controls are imperfect. Shockwave produces a distinctive sensation — patients know they're being treated. Many sham conditions (coupling gel without energy delivery, very low energy delivery) are partially convincing but not identical, so placebo effects may be inflated in the active treatment arms.

Protocols vary enormously between trials. Energy flux density, number of pulses, frequency, treatment intervals, and number of sessions differ across studies in ways that make pooling difficult. A 'shockwave' meta-analysis frequently combines trials that may have used fundamentally different protocols.

Co-interventions are rarely well-controlled. When both groups receive exercise but at variable doses, and shockwave is layered on top, it's difficult to isolate the shockwave effect.

Follow-up is frequently short. Many positive trials report outcomes at 6–12 weeks. Long-term follow-up (12 months+) is less common, and the benefit at longer intervals is less clear.

Clinical Application: When I Use Shockwave

Given all of the above, here's how I currently think about shockwave in tendinopathy management.

Shockwave is most useful as an adjunct in patients where pain is significantly limiting engagement in loading — particularly in the early phase of a programme when even isometric exercises provoke unacceptable symptoms. It can provide enough pain reduction to open a window for loading to begin.

Insertional Achilles tendinopathy with calcific changes is probably the presentation where I have the most confidence in its standalone contribution — the calcific disruption mechanism has reasonable support and something genuinely structural is being addressed.

I'm more cautious about using it as a primary or repeated treatment in patients who haven't yet had a properly structured, progressively loaded exercise programme. In this population, the risk is that short-term symptom improvement from shockwave is interpreted as recovery — loading is not addressed — and symptoms return when provocative activity resumes.

"The conversation I have most often with patients who've had shockwave is: 'It helped for a while, but then it came back when I started doing X again.' That's the load-capacity gap talking — not a failure of shockwave, but evidence that the structural issue was never addressed."

Practical Considerations for Clinicians

If you're referring patients for shockwave, a few practical points are worth noting.

Ensure the patient has a concurrent loading programme. Shockwave alone, without exercise, is suboptimal management and the literature doesn't support it as a standalone approach in most presentations.

Clarify the device being used. There is meaningful variation between f-ESWT and radial pressure wave therapy, and both are sometimes marketed under the 'shockwave' label. For insertional pathology and deeper structures, focused delivery is mechanistically preferable.

Contraindications include active malignancy, open growth plates in skeletally immature patients, blood coagulation disorders, pregnancy, and pacemakers near the treatment site. These should be screened before referral.

Three to five sessions is a typical clinical trial protocol. Clinical 'add more sessions if not responding' approaches are common but have less evidentiary basis.

Summary: Where This Leaves Us

Shockwave therapy is a legitimate tool in the tendinopathy management toolkit. The evidence supports a modest but real analgesic and possibly tissue-modifying effect, particularly for Achilles tendinopathy. It is not a primary treatment, should not replace structured loading, and its benefit at longer follow-up intervals is less established than the short-term literature suggests.

The honest clinical position is: shockwave can help some patients get to a place where they can engage with loading. Loading is what drives the long-term recovery. Both have a role; the sequencing and rationale matter.

If you're working in this space and want to discuss the evidence further — or if you're interested in the clinician-focused tendinopathy course I'm developing — I'd genuinely enjoy the conversation.